Client News

Nyxoah Reports First Quarter Financial and Operating Results

Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement

Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program with WEvenamide as Add-On Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)

Formycon Reports Strong Operational Performance and Financial Results for First Quarter of 2025

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

Galimedix Therapeutics Completes Single Ascending Dose Part of Phase 1 Study with Oral Mmall Molecule, GAL-101, an Amyloid Beta Aggregation Modulator

AFYREN and Südzucker Celebrate 5 Years of Strategic Bioeconomy Partnership

InflaRx to Report First Quarter 2025 Results on May 7, 2025

PL BioScience Launches World’s Only Patented Gamma-irradiated Human Platelet Lysate

Hoffmann & Partner and High Tech Services Join Forces to Build the Leading Financial Services Platform for Life Sciences Companies in the DACH Region